EpiBiome, a precision microbiome engineering company, secured $1 million in debt financing from Silicon Valley Bank (SVB). The financing will allow EpiBiome to ramp up automation and to advance its drug development efforts, as well as purchase additional lab equipment for its new facility.

“SVB has been an incredible strategic partner to us – one that goes beyond the services a traditional bank would provide,” said Dr. Aeron Tynes Hammack, EpiBiome’s co-founder and chief operating officer.

“They’ve helped connect us with corporate partners and investors while also producing life sciences reports that perfectly analyze our target markets. These insights and connections have played a significant role in our success.”

This financing announcement follows the January close of EpiBiome’s $6 million series A funding round. Leading next-generation sequencing investors from the round included: Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group.